MicroRNA-7 enhances cytotoxicity induced by gefitinib in non-small cell lung cancer via inhibiting the EGFR and IGF1R signalling pathways

Jun-gang Zhao; Wan-fu Men; Jun Tang

doi:10.5114/wo.2015.52655

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2015
vol. 19

Send email

Copy url:

abstract:

Original paper

MicroRNA-7 enhances cytotoxicity induced by gefitinib in non-small cell lung cancer via inhibiting the EGFR and IGF1R signalling pathways

Jun-gang Zhao

,

Wan-fu Men

,

Jun Tang

Contemp Oncol (Pozn) 2015; 19 (3): 201–206

DOI: https://doi.org/10.5114/wo.2015.52655

Online publish date: 2015/07/08

View full text Get citation

PlumX metrics:

Gefitinib is a tyrosine kinase inhibitor that has been used for the treatment of non-small-cell lung carcinoma (NSCLC). The ability of miR-7 to enhance gefitinib-induced cytotoxicity in NSCLC cells was evaluated in this study. We found that miR-7 significantly decreased the IC50 of gefitinib and inhibited cell growth. G0/G1 cell cycle arrest and cell apoptosis were increased after the treatment of gefitinib coupled with miR-7 transfection. In addition, levels of Raf1, IGF1R, and PI3K and phosphorylation levels of Akt and ERK were also significantly decreased. Our results suggest that miR-7 may provide a novel therapeutic target for the treatment of NSCLCs.

keywords:

MicroRNA-7 enhances cytotoxicity induced by gefitinib in non-small cell lung cancer via inhibiting the EGFR and IGF1R signalling pathways

Jun-gang Zhao , Wan-fu Men , Jun Tang

non-small-cell lung carcinoma, gefitinib, miR-7, epidermal growth factor receptor

Jun-gang Zhao

,

Wan-fu Men

,

Jun Tang